These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 26392766

  • 21. Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
    Salomon J, Stolz D, Domenighetti G, Frey JG, Turk AJ, Azzola A, Sigrist T, Fitting JW, Schmidt U, Geiser T, Wild C, Kostikas K, Clemens A, Brutsche M.
    Respir Res; 2017 Jan 11; 18(1):13. PubMed ID: 28077140
    [Abstract] [Full Text] [Related]

  • 22. Bronchodilators for hyperinflation in COPD associated with biomass smoke: clinical trial.
    Ramírez-Venegas A, Velázquez-Uncal M, Aranda-Chávez A, Guzmán-Bouilloud NE, Mayar-Maya ME, Pérez Lara-Albisua JL, Hernández-Zenteno RJ, Flores-Trujillo F, Sansores RH.
    Int J Chron Obstruct Pulmon Dis; 2019 Jan 11; 14():1753-1762. PubMed ID: 31496674
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences.
    Ohno T, Wada S, Hanada S, Sawaguchi H, Muraki M, Tohda Y.
    Int J Chron Obstruct Pulmon Dis; 2014 Jan 11; 9():107-14. PubMed ID: 24489464
    [Abstract] [Full Text] [Related]

  • 24. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD.
    Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG.
    Respir Med; 2013 Jun 11; 107(6):848-53. PubMed ID: 23490225
    [Abstract] [Full Text] [Related]

  • 25. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
    Kerwin EM, Williams J.
    Ther Adv Respir Dis; 2013 Feb 11; 7(1):25-37. PubMed ID: 23296242
    [Abstract] [Full Text] [Related]

  • 26. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
    Laforce C, Aumann J, de Teresa Parreño L, Iqbal A, Young D, Owen R, Higgins M, Kramer B, INTEGRAL Study Investigators.
    Pulm Pharmacol Ther; 2011 Feb 11; 24(1):162-8. PubMed ID: 20619353
    [Abstract] [Full Text] [Related]

  • 27. Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD.
    Rogliani P, Ora J, Ciaprini C, Senis L, Stirpe E, Cazzola M.
    Respir Med; 2014 Feb 11; 108(2):307-13. PubMed ID: 24238769
    [Abstract] [Full Text] [Related]

  • 28. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD.
    O'Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D, Kramer B, INABLE 1 study group.
    Respir Med; 2011 Jul 11; 105(7):1030-6. PubMed ID: 21498063
    [Abstract] [Full Text] [Related]

  • 29. Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial.
    Kato M, Makita H, Uemura K, Fukuchi Y, Hosoe M, Emery C, Higgins M, Kramer B.
    Allergol Int; 2010 Sep 11; 59(3):285-293. PubMed ID: 20567133
    [Abstract] [Full Text] [Related]

  • 30. The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.
    Kerstjens HA, Deslée G, Dahl R, Donohue JF, Young D, Lawrence D, Kornmann O.
    Pulm Pharmacol Ther; 2015 Jun 11; 32():101-8. PubMed ID: 25743376
    [Abstract] [Full Text] [Related]

  • 31. Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients.
    Mroz RM, Minarowski L, Chyczewska E.
    Adv Exp Med Biol; 2013 Jun 11; 756():23-8. PubMed ID: 22836615
    [Abstract] [Full Text] [Related]

  • 32. Indacaterol and tiotropium combination therapy in patients with chronic obstructive pulmonary disease.
    Matsushima S, Inui N, Yasui H, Kono M, Nakamura Y, Toyoshima M, Shirai T, Suda T.
    Pulm Pharmacol Ther; 2015 Feb 11; 30():11-5. PubMed ID: 25445929
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators.
    Thorax; 2010 Jun 11; 65(6):473-9. PubMed ID: 20522841
    [Abstract] [Full Text] [Related]

  • 34. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M.
    Pulm Pharmacol Ther; 2007 Jun 11; 20(6):740-9. PubMed ID: 17088091
    [Abstract] [Full Text] [Related]

  • 35. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
    Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, Cameron R, Shoaib M, Lawrence D, Young D, McBryan D, INVIGORATE investigators.
    Lancet Respir Med; 2013 Sep 11; 1(7):524-33. PubMed ID: 24461613
    [Abstract] [Full Text] [Related]

  • 36. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D, LANTERN Investigators.
    Int J Chron Obstruct Pulmon Dis; 2015 Sep 11; 10():1015-26. PubMed ID: 26082625
    [Abstract] [Full Text] [Related]

  • 37. Indacaterol: a comprehensive review.
    Rossi A, Polese G.
    Int J Chron Obstruct Pulmon Dis; 2013 Sep 11; 8():353-63. PubMed ID: 23922496
    [Abstract] [Full Text] [Related]

  • 38. Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial.
    Divo MJ, DePietro MR, Horton JR, Maguire CA, Celli BR.
    Respir Res; 2020 Jan 20; 21(1):26. PubMed ID: 31959167
    [Abstract] [Full Text] [Related]

  • 39. Bronchodilator effects of indacaterol and formoterol in patients with COPD.
    Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S.
    Pulm Pharmacol Ther; 2009 Dec 20; 22(6):492-6. PubMed ID: 19465142
    [Abstract] [Full Text] [Related]

  • 40. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
    Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M.
    Respir Med; 2008 Jul 20; 102(7):1033-44. PubMed ID: 18479895
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.